Coya Therapeutics (Coya Therapeutics) EBITDA Margin % : -4,292.13% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Coya Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Coya Therapeutics's EBITDA for the three months ended in Mar. 2024 was $-5.45 Mil. Coya Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.13 Mil. Therefore, Coya Therapeutics's EBITDA margin for the quarter that ended in Mar. 2024 was -4,292.13%.

Coya Therapeutics EBITDA Margin % Historical Data

The historical data trend for Coya Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coya Therapeutics EBITDA Margin % Chart

Coya Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

-122.18

Coya Therapeutics Quarterly Data
	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBITDA Margin %	Get a 7-Day Free Trial						-	-	-	33.57	-4,292.13

Competitive Comparison of Coya Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Coya Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coya Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coya Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Coya Therapeutics's EBITDA Margin % falls into.

Coya Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Coya Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-7.333	/	6.002
	=	-122.18 %

Coya Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-5.451	/	0.127
	=	-4,292.13 %

Coya Therapeutics (NAS:COYA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Coya Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Coya Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Coya Therapeutics (Coya Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coya Therapeutics Inc (NAS:COYA) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

5850 San Felipe Street, Suite 500, Houston, TX, USA, 77057

Website

https://www.coyatherapeutics.com

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Executives

Dieter Weinand	director	C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Fred Grossman	officer: Chief Medical Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Goldstein Dov A Md	director
Adrian Hepner	officer: Chief Medical Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
David S Snyder	officer: Chief Financial Officer	ONE SCIENCE COURT, MADISON WI 53711
Hideki Garren	director	C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Anabella Villalobos	director	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Howard Berman	director, 10 percent owner, officer: Chief Executive Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Ann Lee	director	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Bertex Llc	10 percent owner	5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057